Related Experiment Video
Updated: Aug 12, 2026
09:46
Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
Published on: September 14, 2009
Development of a platform to evaluate and limit in-stent restenosis
C J Elkins1, J M Waugh, P G Amabile
1Cardiovascular and Interventional Radiology, Stanford University School of Medicine, 300 Pasteur Drive H3648, Stanford, CA 94305, USA.
Tissue Engineering
|August 9, 2002
Summary
A novel drug delivery stent platform effectively manages in-stent restenosis without altering inflammation or plaque formation. This system enables evaluation and local delivery of therapeutic agents for cardiovascular disease treatment.
Area of Science:
- Biomedical Engineering
- Cardiovascular Research
- Drug Delivery Systems
Background:
- In-stent restenosis (ISR) is a significant complication following angioplasty and stenting, leading to re-narrowing of arteries.
- Current methods for evaluating or treating ISR often perturb the arterial system, limiting their efficacy.
- There is a critical need for a localized drug delivery platform that can assess and treat ISR without adverse effects.
Purpose of the Study:
- To develop and validate a novel drug delivery platform for the evaluation and local management of in-stent restenosis.
- To create a stent-based system capable of delivering therapeutic agents directly to the site of restenosis.
- To assess the safety and efficacy of this platform in preclinical models.
Main Methods:
- Modification of a balloon-expandable stainless steel stent into an ablumenal drug delivery system.
- Evaluation of various bioerodible polymer microsphere and gel combinations for drug retention.
- In vitro flow and in vivo studies to assess material embolization and platform performance.
- Comparison of the modified stent's impact on inflammation and plaque formation against conventional stents.
Main Results:
- A stent-anchored hybrid drug delivery system was successfully developed, preventing material embolization under all tested conditions.
- The developed stent platform did not alter local inflammation or in-stent plaque formation compared to conventional stents post-deployment.
- The system demonstrated sensitivity in detecting plaque reduction when an antirestenotic agent was delivered.
Conclusions:
- A functional platform for the evaluation and local delivery of therapeutic agents for in-stent restenosis has been successfully achieved.
- This novel stent system offers a promising approach for managing ISR by enabling targeted drug delivery and assessment.
- The platform's ability to deliver agents without exacerbating inflammation or plaque makes it a valuable tool for cardiovascular disease research and treatment.
